[{"id":"2dc4eb4c-eda6-4d7f-bf25-c974b4ee8106","acronym":"CO43805","url":"https://clinicaltrials.gov/study/NCT05169515","created_at":"2021-12-27T15:54:16.180Z","updated_at":"2025-02-25T15:27:09.973Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05169515 - CO43805","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 03/07/2027","primary_completion_date":" 03/07/2027","study_txt":" Completion: 03/07/2029","study_completion_date":" 03/07/2029","last_update_posted":"2025-02-10"},{"id":"fe939754-1cac-4f5a-b6b4-bf23ef9b33d0","acronym":"PLATFORM","url":"https://clinicaltrials.gov/study/NCT03310619","created_at":"2021-01-18T16:21:00.823Z","updated_at":"2024-07-02T16:35:11.345Z","phase":"Phase 1/2","brief_title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT03310619 - PLATFORM","lead_sponsor":"Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imfinzi (durvalumab) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel) • avadomide (CC-122) • iberdomide (CC-220) • relatlimab (BMS-986016) • golcadomide (CC-99282)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 12/20/2017","start_date":" 12/20/2017","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2024-04-04"},{"id":"92b33b60-daf2-458f-b368-c4bd957a3d7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05354557","created_at":"2022-04-29T11:55:52.474Z","updated_at":"2024-07-02T16:35:22.512Z","phase":"Phase 2","brief_title":"Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)","source_id_and_acronym":"NCT05354557","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e iberdomide (CC-220)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 04/26/2025","primary_completion_date":" 04/26/2025","study_txt":" Completion: 04/26/2025","study_completion_date":" 04/26/2025","last_update_posted":"2024-01-23"},{"id":"d361ee88-d87a-4fe2-9be4-8b2ce4671cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04464798","created_at":"2021-07-05T17:31:08.177Z","updated_at":"2024-07-02T16:35:34.824Z","phase":"Phase 1/2","brief_title":"A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas","source_id_and_acronym":"NCT04464798","lead_sponsor":"Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Gazyva (obinutuzumab) • iberdomide (CC-220)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 01/02/2025","study_completion_date":" 01/02/2025","last_update_posted":"2023-10-04"},{"id":"6ff06964-4a4d-4f6c-8623-c8cc6737eeca","acronym":"","url":"https://clinicaltrials.gov/study/NCT04882163","created_at":"2021-05-11T11:53:08.827Z","updated_at":"2024-07-02T16:36:23.460Z","phase":"Phase 1b/2","brief_title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","source_id_and_acronym":"NCT04882163","lead_sponsor":"Celgene","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • bendamustine • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • iberdomide (CC-220)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2021","start_date":" 10/10/2021","primary_txt":" Primary completion: 04/08/2026","primary_completion_date":" 04/08/2026","study_txt":" Completion: 04/07/2029","study_completion_date":" 04/07/2029","last_update_posted":"2021-10-05"}]